1.Confirmed diagnosis of hepatocellular carcinoma 1.Pathological diagnostic criteria: biopsy or surgical excision of tissue specimens from liver occupying lesions or extrahepatic metastases, diagnosed as HCC by pathological histology and/or cytology, which is the gold standard. 2, clinical diagnostic criteria: in all recognized, non-invasive, easy and convenient and strong operable, generally considered to depend mainly on three major factors, namely, chronic liver disease background, imaging findings and serum AFP level; however, academic recognition and specific requirements vary and often change, and there are errors in practical application, therefore, combined with China’s national conditions, previous domestic standards and clinical solid tumors, the only HCC can be used clinical diagnostic criteria, both domestic and foreign bed practical, the expert group proposed that it is appropriate to strictly grasp and joint analysis, requiring that the clinical diagnosis of HCC can be established when both (1)+(2)a two or (1)+(2)b+(3) three of the following conditions are met: (1) with cirrhosis and HBV and/or HCV infection (HBV and/or HCV antigen-positive) Evidence. (2) Typical HCC imaging features: simultaneous multi-row CT scan and/or dynamic contrast-enhanced MRI demonstrating rapid heterogeneous vascular enhancement of the hepatic occupancy in the arterial phase with rapid elution in the venous or delayed phase. (1) If the diameter of liver occupancy is ≥2 cm, one of the two imaging examinations of CT and MRI shows that the liver occupancy has the characteristics of hepatocellular carcinoma mentioned above, HCC can be diagnosed. (2) If the diameter of liver occupancy is 1-2 cm, both imaging examinations of CT and MRI need to show that the liver occupancy has the characteristics of hepatocellular carcinoma mentioned above before HCC can be diagnosed to enhance the specificity of diagnosis. (3) Serum AFP ≥400μg/L for 1 month or ≥200μg/L for 2 months, and other causes of elevated AFP can be excluded, including pregnancy, germline embryonic-derived tumor, active liver disease and secondary liver cancer. What should I do if I am diagnosed with hepatocellular carcinoma? Early resection is the key to improve the survival rate, and the smaller the tumor, the higher the five-year survival rate. The indications for surgery are: 1. clear diagnosis, estimated lesion is limited to one lobe or half liver; 2. no obvious jaundice, ascites or distant metastasis; 3. liver function is still well compensated and prothrombin time is not less than 50%; 4. heart, liver and kidney function tolerance. In those with normal liver function, the amount of liver resection should not exceed 70%; in those with moderate cirrhosis, it should not exceed 50%, or only the left half of the liver can be resected; in severe cirrhosis, lobectomy cannot be performed. Surgery and pathology confirm that more than 80% of hepatocellular carcinoma is combined with cirrhosis, and it is recognized that local resection instead of regular lobectomy has the same effect, while postoperative liver dysfunction is reduced and surgical mortality is also reduced. Since radical resection still has a high recurrence rate, it is advisable to review AFP and ultrasound imaging regularly after surgery to monitor recurrence. Because of the close follow-up after radical resection, small hepatocellular carcinoma with recurrence in the “subclinical stage” is often detected, and reoperation is preferred. Although liver transplantation is a treatment for liver cancer and has been reported more frequently abroad, its status in the treatment of liver cancer has not been confirmed for a long time, and patients often die of recurrence due to the application of long-term immunosuppressive drugs after surgery. Once liver cancer has progressed to advanced stage, most patients have lost the best chance of surgical treatment, and the treatment at this time is aimed at reducing the pain of liver cancer patients and prolonging their survival time. The reasonable combination of hepatic artery embolization intervention and radiotherapy can effectively prolong the survival time of advanced liver cancer patients and improve the quality of survival.